Industry News

The latest news from the clinical trials industry.

News Powered By:

– a collaborative partner.


LabCorp announces new Covance leadership

CenterWatch News Online Headlines : July 30, 2015 5:31 am : Centerwatch

Deborah Keller will succeed Joseph Herring as chief executive officer of Covance Drug Development. Herring will retire July 31 after more than a decade as chief executive officer.

ICON, Mereo BioPharma partner for clinical development

CenterWatch News Online Headlines : July 30, 2015 5:30 am : Centerwatch

Global CRO Icon, based in Dublin, has partnered with Mereo BioPharma Group, a London-based, recently formed specialty biopharmaceutical company. Icon will be the sole provider of clinical development services to Mereo.

EMA approves GSK’s Malaria vaccine

CenterWatch News Online Headlines : July 29, 2015 6:50 am : Centerwatch

GlaxoSmithKline (GSK) has received a positive opinion for its malaria vaccine candidate from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. The vaccine candidate Mosquirix (RTS,S) is the first QS-21 Stimulon containing product to receive a positive regulatory decision.

Greenphire appoints Sue Vestri new chief financial officer

CenterWatch News Online Headlines : July 29, 2015 6:49 am : Centerwatch

Greenphire, a King of Prussia, Pa.-based provider of payment technologies for the clinical trials industry, has appointed Sue Vestri as chief financial officer. Vestri will be responsible for developing and driving the financial strategy for Greenphire, including working with the senior team to drive the company’s mission and help execute its growth plans.

Progenics receives FDA Breakthrough Therapy for Azedra

CenterWatch News Online Headlines : July 29, 2015 6:48 am : Centerwatch

The FDA has designated Progenics Pharmaceuticals’ Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma. Azedra currently is being evaluated in a pivotal phase IIb trial, which is being conducted under a Special Protocol Assessment Agreement (SPA), and has received Orphan Drug and Fast Track designations from the FDA.

« Page 1, 2, 3148, »